|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9122
|
|
pubmed:dateCreated |
1998-7-28
|
|
pubmed:abstractText |
Tamoxifen, a drug with antioestrogenic effects, is predicted to prevent the occurrence of breast cancer. We have undertaken a trial of tamoxifen in healthy women who are at increased risk of breast cancer because of family history. We report a planned interim analysis.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0140-6736
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
11
|
|
pubmed:volume |
352
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
98-101
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9672274-Adult,
pubmed-meshheading:9672274-Aged,
pubmed-meshheading:9672274-Anticarcinogenic Agents,
pubmed-meshheading:9672274-Breast Neoplasms,
pubmed-meshheading:9672274-Disease-Free Survival,
pubmed-meshheading:9672274-Double-Blind Method,
pubmed-meshheading:9672274-Estrogen Replacement Therapy,
pubmed-meshheading:9672274-Female,
pubmed-meshheading:9672274-Follow-Up Studies,
pubmed-meshheading:9672274-Humans,
pubmed-meshheading:9672274-Incidence,
pubmed-meshheading:9672274-Middle Aged,
pubmed-meshheading:9672274-Patient Compliance,
pubmed-meshheading:9672274-Tamoxifen
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
|
|
pubmed:affiliation |
Royal Marsden NHS Trust, London and Sutton, Surrey, UK. trevor.powles@rmh.nthames.nhs.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
